Investors

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its innovative delivery platform. At Vaxart, we are revolutionizing how the immune system responds and the way immunizations are delivered with our oral pill vaccine.

Vaxart’s oral pill vaccines are designed to generate durable mucosal and systemic immunity, offering a potentially innovative advance in immunization technology. Our vaccines are intended to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury.

Our diverse pipeline of prophylactic and therapeutic vaccines targets a range of infectious diseases. Vaxart believes that our proprietary platform is suitable to develop oral recombinant versions of currently marketed products and new indications. Vaxart’s development program currently includes oral pill vaccines designed to protect against COVID-19, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral pill immunization using adenovirus and TLR3 agonists.